Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study)

BACKGROUND: An exploratory, proof-of-concept, liquid biopsy addendum to examine biomarkers within cell-free DNA (cfDNA) in the RELAY phase 3, randomized, double-blind, placebo-controlled study was conducted. RELAY showed improved progression-free survival (PFS) with ramucirumab (RAM), a human immuno...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishio, Kazuto, Sakai, Kazuko, Nishio, Makoto, Seto, Takashi, Visseren-Grul, Carla, Carlsen, Michelle, Matsui, Tomoko, Enatsu, Sotaro, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483085/
https://www.ncbi.nlm.nih.gov/pubmed/37691865
http://dx.doi.org/10.21037/tlcr-22-736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483085/
https://www.ncbi.nlm.nih.gov/pubmed/37691865
http://dx.doi.org/10.21037/tlcr-22-736

Ejemplares similares